Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral Rehydration Salt Powder (III), marketed under the brand name Baiyansu®, is an approved oral rehydration formulation developed and manufactured by Anhui Jiuhua Huayuan Pharmaceutical. It is a powder formulation containing a specific balance of electrolytes (sodium, potassium, and chloride) and glucose. The product is indicated for the prevention and treatment of mild to moderate dehydration resulting from acute diarrhea and for the replacement of lost fluids and electrolytes. Its mechanism of action relies on the sodium-glucose cotransport system in the small intestine, where glucose facilitates the absorption of sodium and water, thereby restoring fluid and electrolyte balance. This low-osmolarity formulation (245 mOsm/L) is designed to reduce stool output and the need for intravenous fluids compared to older ORS formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oral Rehydration Salt Powder (III).